SCHEMBL5689079

SCHEMBL5689079

Cc1cc(F)cc(C)c1NC(=O)c1cnc(Nc2ccc(OCCCN3CCN(C)CC3)c(F)c2)nc1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.47
LCK P06239 2/20 0.47
SRC P12931 2/20 0.47
MAPK14 Q16539 1/20 0.47
MET P08581 10/20 0.46
CSF1R P07333 2/20 0.44
EGFR P00533 4/20 0.43
BRAF P15056 1/20 0.43
PDGFRB P09619 1/20 0.43
KIT P10721 1/20 0.43
FLT3 P36888 1/20 0.43
TNK2 Q07912 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4497531 0.95 KDR (0.47) KDRLCKSRCMAPK14MET
SCHEMBL5686300 0.93 KDR (0.50) KDRLCKSRCMAPK14MET
SCHEMBL4496504 0.93 KDR (0.52) KDRLCKSRCMAPK14MET
SCHEMBL4503003 0.93 MET (0.45) KDRLCKSRCMAPK14MET
SCHEMBL5689288 0.91 CSF1R (0.48) KDRLCKSRCMAPK14MET
SCHEMBL4500256 0.88 KDR (0.50) KDRLCKSRCMAPK14MET
SCHEMBL5686145 0.88 TNK2 (0.50) KDRLCKSRCMAPK14MET
SCHEMBL5686279 0.88 CSF1R (0.50) KDRLCKSRCMAPK14MET
SCHEMBL4496395 0.87 TNK2 (0.56) KDRLCKSRCMAPK14MET
SCHEMBL4481044 0.86 EGFR (0.47) KDRLCKSRCMAPK14MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed